Jamie Jensen Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 13 Cassotta Ln, Suffield, CT 06078 Phone: 860-836-9980 |
Dr. Derek Gyllenhammer Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 163 Mountain Rd, Suffield, CT 06078 Phone: 860-668-5115 Fax: 860-668-0856 |
Christopher T Farroni, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 163 Mountain Rd, Suffield, CT 06078 Phone: 860-668-5115 |
Dr. Amanda Touch, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 163 Mountain Rd, Suffield, CT 06078 Phone: 860-668-5115 |
Elizabeth Johnston Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 163 Mountain Rd, Suffield, CT 06078 Phone: 860-668-5115 Fax: 860-668-0856 |
News Archive
CureVac AG, a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced it has initiated a Phase I study assessing the intratumoral application of its novel RNAdjuvant technology in patients with superficial solid tumors that are easily accessible for repeated intratumoral injections. RNAdjuvant is designed to amplify the scope and quality of an immune response when used alone or in combination with other immune therapies.
Patients receiving anterior cruciate ligament (ACL) knee reconstruction with a hamstring tendon graft rather than a knee tendon graft were less likely to suffer from pain and mobility issues15 years after surgery, say researchers presenting a study today at the American Orthopaedic Society for Sports Medicine's Specialty Day in San Diego, California (February 19).
W. L. Gore & Associates is sponsoring the EVEResT (European Virtual Reality Endovascular Research Team) Lunch Symposium taking place on Friday, Nov. 19 from 12:00 to 1:00 p.m. at the VEITHsymposium in the Gramercy A room, second floor. The symposium will detail the evidence for simulation in medical training and in other fields. Companies will demonstrate how new simulation technologies are designed to enhance performance in endovascular procedures.
A study conducted by researchers at Thomas Jefferson University, Philadelphia, and published Tuesday, July 27, 2004, in the journal Neurology, shows that Frova (frovatriptan), a triptan class migraine therapy with a long half life, significantly reduced the incidence of menstrual associated migraines (MAM) in women who took the medication preventively, in advance of anticipated onset of headache.
› Verified 5 days ago